Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.4K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
The Ras Gene02:38

The Ras Gene

6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

5.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
3.9K
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

8.4K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of personality on likelihood of contracting SARS-CoV-2 in the United States.

Personality and individual differences·2026
Same author

Precise calcium-to-spike inference using biophysical generative models.

bioRxiv : the preprint server for biology·2026
Same author

Floating Cast in the Ascending Aorta After Impella Removal.

Annals of thoracic surgery short reports·2026
Same author

NF1 and SPRED1/2 cooperate through RAS-MAPK-independent functions.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Anti-A Antibody Rebound-Induced Thrombotic Microangiopathy After ABO-Incompatible Kidney Transplantation: A Case Report.

Transplantation proceedings·2026
Same author

High yield production of C-terminally processed KRAS4a, HRAS, and NRAS for biophysical study.

Protein expression and purification·2026

Related Experiment Video

Updated: Jun 3, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.0K

Structural insights into isoform-specific RAS-PI3Kα interactions and the role of RAS in PI3Kα activation.

Daniel Czyzyk1, Wupeng Yan1,2, Simon Messing1

  • 1NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Nature Communications
|January 9, 2025
PubMed
Summary

RAS and PI3Kα mutations drive cancer by activating the PI3K-AKT-mTOR pathway. This study reveals the structural basis of RAS-PI3Kα interaction, offering targets for isoform-specific cancer inhibitors.

More Related Videos

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry
08:07

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry

Published on: July 26, 2019

8.5K
Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle
10:05

Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle

Published on: March 5, 2019

6.4K

Related Experiment Videos

Last Updated: Jun 3, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.0K
Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry
08:07

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry

Published on: July 26, 2019

8.5K
Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle
10:05

Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle

Published on: March 5, 2019

6.4K

Area of Science:

  • Molecular biology
  • Cancer research
  • Structural biology

Background:

  • Mutations in RAS and PI3Kα are key drivers of human cancers.
  • The RAS-PI3Kα interaction is critical for activating PI3Kα and the PI3K-AKT-mTOR pathway.
  • Understanding this interaction is vital for developing targeted cancer therapies.

Purpose of the Study:

  • To elucidate the structural details of the RAS-PI3Kα interaction.
  • To identify key residues and interfaces involved in binding.
  • To provide a foundation for designing isoform-specific PI3Kα inhibitors.

Main Methods:

  • X-ray crystallography to determine complex structures of KRAS, RRAS2, and MRAS with PI3Kα (p110α).
  • Structural and mutational analyses to assess binding affinities and identify key residues.
  • Comparative analysis of RAS and PI3K isoform interactions.

Main Results:

  • Detailed structures of RAS proteins (KRAS, RRAS2, MRAS) bound to the PI3Kα catalytic subunit (p110α) were determined.
  • Key residues and interaction interfaces governing RAS-PI3Kα binding affinity were identified.
  • RAS interaction with p110α was localized to the RAS-binding domain, excluding the kinase domain.
  • Isoform-specific differences in RAS and PI3K interactions were revealed.

Conclusions:

  • The study provides critical structural insights into the RAS-PI3Kα interaction, a key mechanism in cancer.
  • Identified structural features and isoform-specific differences pave the way for targeted drug design.
  • This work offers a blueprint for developing novel PI3Kα isoform-specific inhibitors to disrupt oncogenic signaling.